References
- The top 10 causes of death, https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
- Kumar V., Cotran R. S., Robbins S. L. 2019. Robbins Patologia. Wyd.10. Wrocław: Edra Urban & Partner.
- Hogg, James C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. The Lancet 364.9435; 2004: 709–721, DOI: 10.1016/S0140–6736(04)16900–6.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 Report. https://goldcopd.org/2023-gold-report-2/
- Wang, L., Xie, J., Hu, Y., i in. Air pollution and risk of chronic obstructed pulmonary disease: the modifying effect of genetic susceptibility and lifestyle. EBioMedicine, 2022, 79, doi: 10.1016/j. ebiom.2022.103994.
- Polverino, F., & Celli, B. The challenge of controlling the COPD epidemic: unmet needs. The American journal of medicine, 2018, 131(9), 1–6, doi.org/10.1016/j.amjmed.2018.05.001.
- Shrikrishna D, Hopkinson NS. Chronic obstructive pulmonary disease: consequences beyond the lung. Clin Med (Lond), 2012 Feb, 12(1):71–4, doi: 10.7861/clinmedicine.12–1-71.
- Kalfopoulos M, Wetmore K, ElMallah MK. Pathophysiology of Alpha-1 Antitrypsin Lung Disease. Methods Mol Biol. 2017;1639:9–19, doi: 10.1007/978–1-4939–7163–3_2.
- Agustí A, Celli BR, Criner GJ, i in. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023 Apr 1;61(4):2300239, doi: 10.1183/13993003.00239–2023.
- Rossaki, F. M., Hurst, J. R., van Gemert, F., i in. Strategies for the prevention, diagnosis and treatment of COPD in low- and middle- income countries: the importance of primary care. Expert Review of Respiratory Medicine, 2021, 15(12), 1563–1577, https://doi.org/10.1080/17476348.2021.1985762.
- Kalfopoulos M, Wetmore K, ElMallah MK. Pathophysiology of Alpha-1 Antitrypsin Lung Disease. Methods Mol Biol. 2017;1639:9–19, doi: 10.1007/978–1-4939–7163–3_2.
- Białas A. J., Postępowanie w POChP – co nowego w raporcie GOLD 2023. Cz. 2. Rozpoznanie -strona 2, Medycyna Praktyczna, 02.08.2023, https://www.mp.pl/pulmonologia/artykuly-wytyczne/pochp/328226,postepowanie-w-pochp-raport-gold-2023-cz-2-rozpoznanie,1.
- Wytyczne konsultanta krajowego w dziedzinie chorób płuc oraz konsultanta krajowego w dziedzinie medycyny rodzinnej dotyczące diagnostyki i leczenia POCHP w POZ, z uwzględnieniem opieki koordynowanej z dnia 16 lutego 2024 https://koordynowana.nfz.gov.pl/wp-content/uploads/2024/02/Wytyczne-konsultantow-krajowych-dot.-POCHP-w-opiece-koordynowanej.pdf.
- Stanojevic, S., Kaminsky, D. A., Miller, M. R., i in. ERS/ATS technical standard on interpretive strategies for routine lung function tests. European Respiratory Journal, 2022, 60(1), doi. org/10.1183/13993003.01499–2021.
- Nowości w praktyce. Klinika Chorób Wewnętrznych, Astmy i Alergii, Uniwersytet Medyczny w Łodzi, https://podyplomie.pl/medycyna/10620,nowosci-w-praktyce?page=7&srsltid=AfmBOop5gDUu9H1LWX8fZgr_lu1P5DZbljv1pEkN2yUazWMsnCPHC5qp.
- Yorke, J., Khan, N., Garrow, A., i in., Evaluation of the Individual Activity Descriptors of the mMRC Breathlessness Scale: A Mixed Method Study. International Journal of Chronic Obstructive Pulmonary Disease, 2022, 17, 2289–2299, doi.org/10.2147/COPD.S372318.
- Gil HI, Zo S, Jones PW, i in., Clinical Characteristics of COPD Patients According to COPD Assessment Test (CAT) Score Level: Cross-Sectional Study. Int J Chron Obstruct Pulmon Dis. 2021 Jun 1;16:1509–1517, doi: 10.2147/COPD.S297089.
- Labaki, W. W., Martinez, C. H., Martinez, F. J.,i in., The role of chest computed tomography in the evaluation and management of the patient with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2017, 196(11), 1372–1379, doi.org/10.1164/ rccm.201703–0451PP.
- Dahl, M., Vestbo, J., Zacho, J., i in., C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax, 2011, 66(3), 197–204, doi.org/10.1136/thx.2009.131193.
- Haroon, S., Jordan, R., Takwoingi, Y., i in. Diagnostic accuracy of screening tests for COPD: a systematic review and meta-analysis. BMJ open, 2015, 5(10), e008133, doi.org/10.1136/ bmjopen-2015–008133.
- Gajewski, P., Jaeschke, R., Budaj, A., Interna Szczeklika 2024.
- Chazan, R. New therapeutic possibilities — COPD. Pneumonologia i Alergologia Polska, 2013, 81(2),154.
- Raport w sprawie zalecanych technologii medycznych, działań przeprowadzanych w ramach programów polityki zdrowotnej oraz warunków realizacji tych programów Raport nr: OT.423.6.2018.
- Karunarathna, I., De Alvis, K., Gunasena, P., i in., Perioperative and intensive care management of chronic obstructive pulmonary disease (COPD) patients: A comprehensive review. 2024.
- Xu, J., Zeng, Q., Li, S., i in., Inflammation mechanism and research progress of COPD. Frontiers in Immunology, 2024, 15, 1404615, doi.org/10.3389/fimmu.2024.1404615.
- Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol, 2016, 138:16–27, doi: 10.1016/j.jaci.2016.05.011.
- Barnes PJ. Endotypy zapalne w POChP. Alergia. 2019, 74:1249–56, doi: 10.1111/all.13760.
- Cobb, K., Kenyon, J., Lu, J., i in., COPD is associated with increased cardiovascular disease risk independent of phenotype. Respirology. 2024, doi.org/10.1111/resp.14799.
- Fazleen, A., Wilkinson, T. Early COPD: current evidence for diagnosis and management. Therapeutic advances in respiratory disease, 2020, 14, 1753466620942128, https://doi.org/10.1177/1753466620942128.
- Koga, Y., Deguchi, S., Matsuo, T., i in. Underdiagnosis of COPD: The Japan COPD Real World Data Epidemiological (CORE) Study. International Journal of Chronic Obstructive Pulmonary Disease, 2024, 19, 1011–1019, https://doi.org/10.2147/COPD.S450270.